High impact, high value, evidence-based therapies for the treatment of cardiovascular diseases

Learn More

Addressing Unmet Cardiovascular Needs

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, affect large patient populations and drive a significant portion of healthcare costs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year or 31% of all global deaths according to the World Health Organization. Cardiovascular diseases are the leading cause of death in the U.S. as well, causing 774,165 deaths or over 28.5% of all deaths in 2015 according to the CDC. Despite medical advancements, there remains significant need for improvement in clinical outcomes associated with cardiovascular disease.

[   17.7M people die every year from cardiovascular diseases   ]

Product Pipeline Overview

Product pipeline targets large initial markets with significant growth opportunities in expansion future indications.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies target clear unmet needs in high risk patients

News & Events

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)

November 8, 2018

  • Novel Treatment Delivers Immediate, Substantial, and Sustained Reduction in Blood Pressure
  • Potential to Become a Broadly Applicable Therapy for Device-Based Hypertension Management

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

October 10, 2018

  • Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions
  • Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions
  • Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation

Read All News